Cognition Therapeutics says USPTO allows zervimesine patent application extending protection to 2045

Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc.

CGTX

0.00
  • Cognition Therapeutics received a USPTO Notice of Allowance for a composition-of-matter patent application covering a crystalline form of zervimesine (CT1812).
  • Once issued, the patent would extend U.S. protection for the lead candidate through 2045, with a potential 5-year extension to 2050.
  • The application also covers a proprietary manufacturing process, with the company planning to use the new form in registrational trials for DLB psychosis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160730PRIMZONEFULLFEED9747496) on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.